NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors
Status:
Completed
Trial end date:
2019-09-25
Target enrollment:
Participant gender:
Summary
This is an open-label Phase I study to evaluate the safety, tolerability, and
pharmacokinetics of escalating oral doses of NLG802, an investigational agent intended to
inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme and help the human immune system
attack solid tumor cells more effectively.